– Consolidated turnover after application of IFRS 5 of €19.4 million, +11.3% at constant exchange rates
– Revenue before IFRS 5 application (Extremities activities included) of €23.9 million, +14.1% at constant exchange rates
– Continued growth in extremity activities (Novastep): +28.8% at constant exchange rates
Valence, November 24, 2022, 6:00 p.m. CET – Amplitude Surgical (ISIN: FR0012789667, Mnémo: AMPLI, PEA-PME eligible), French leader on the market for surgical technologies intended for orthopedics for the lower limbs, announces its turnover of business for the first quarter of fiscal year 2022-23.
Olivier Jallabert, Chief Executive Officer of Amplitude Surgical, declares: “During the first quarter of the 2022-23 financial year, Amplitude Surgical posted an increase in Group turnover before application of IFRS 5 of 14.1%. benefiting from almost normal availability of operating rooms, which was not the case during the first quarter of the previous financial year. Knee and hip activities posted an increase of 11.3% at constant rates. Novastep continued its development to represent approximately 18.8% of the Group’s turnover before application of the IFRS 5 standard, with growth of nearly 29% during the period”.